upndown1313

Is ViroPharma a Buy Despite Seemingly Weak Fundamentals?

Tony Kent does not know how to value a biotech. Let's see for Camvia, potential $500M market, and 90% POS starting in 2009. You do the math. It isn't that hard. Not suprising that the tutes have been loading up for quite a while now.